Heteroaromatic Methyl Cyclic Amine Derivatives as Orexin Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sleep disorders, depression, anxiety disorders, and other conditions lack effective compounds with good pharmacokinetics and safety profiles that also exhibit orexin receptor antagonistic activity.
Innovation Solution
Development of novel heteroaromatic methyl cyclic amine derivatives, specifically compounds represented by certain formulae, which act as orexin receptor antagonists, offering good pharmacokinetics and safety alongside effective antagonistic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing OX receptor antagonist compounds are used, then orexin receptor antagonistic activity is achieved, but pharmacokinetics and safety profiles are insufficient
Solution Approach 1:
The patent modifies molecular parameters of OX receptor antagonist compounds by changing the core skeleton structure from heteroaromatic rings to heteroaromatic methyl cyclic amine derivatives, adjusting substituent groups, and optimizing molecular weight and lipophilicity to achieve better pharmacokinetic properties and safety profiles while maintaining antagonistic activity
Solution Approach 2:
The invention creates composite molecular structures by combining heteroaromatic groups with methyl cyclic amine scaffolds, integrating multiple functional groups (such as pyridyl, pyrimidinyl, triazolyl with oxazolidine or oxazinane rings) to achieve both high receptor affinity and improved pharmacokinetic characteristics
2Reliability
If novel heteroaromatic methyl cyclic amine derivatives are developed, then pharmacokinetics and safety are improved, but compound novelty and structural complexity increase
Solution Approach 1:
The patent divides the molecule into distinct functional segments: a heteroaromatic group (pyridyl, pyrimidinyl, triazolyl), a linker moiety, and a methyl cyclic amine core (oxazolidine or oxazinane ring), allowing systematic optimization of each segment to balance complexity with desired pharmacokinetic properties
Solution Approach 2:
The invention introduces specific local structural features such as methyl substitutions at defined positions on the cyclic amine ring, specific heteroaromatic group attachments, and controlled substitution patterns to achieve optimal pharmacokinetics without excessive overall molecular complexity
Data Source
AI summary
A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (OX) receptor antagonist activity.